Results 111 to 120 of about 389,869 (294)
A novel interpenetrating network hydrogel microsphere (NSC‐Exos@HIMS) is developed to manipulate oxygen tension in damaged regions and recruit endogenous stem cells. In vitro and in vivo results show that NSC‐Exos@HIMS maintains the hypoxia microenvironment for up to 5 days, which triggers nucleus pulposus cell‐like differentiation and enhanced ECM ...
Xingdie Zhou+9 more
wiley +1 more source
LGR6 overexpression ameliorates cardiac hypertrophy by regulating metabolic reprogramming through USP4‐PPARα pathway. Abstract Metabolic reprogramming is a pivotal mechanism in the pathogenesis of pathological cardiac hypertrophy. Leucine‐rich repeat‐containing G protein‐coupled receptor 6 (Lgr6) has emerged as a significant player in cardiovascular ...
Mengmeng Zhao+7 more
wiley +1 more source
Factors Influencing Survival after Human Heart Transplantation
Grady L. Hallman+6 more
openalex +2 more sources
A unique hydrogel based on extracellular matrix from fish swim bladder, which is suitable for transcatheter delivery and possesses remarkable reparative capabilities for treating heart failure, is developed. It emerges as a multi‐effect factor profoundly influencing inflammation regulation, angiogenesis, and myocardial metabolism.
Yulong Fu+9 more
wiley +1 more source
Anesthesia for Major Operations on Patients Who Have Transplanted Hearts, A Review of 29 Cases [PDF]
Steven F. Kanter, Stanley I. Samuels
openalex +1 more source
Novel Electroactive Therapeutic Platforms for Cardiac Arrhythmia Management
Electroactive platforms offer promising applications in cardiac arrhythmia. Based on their energy sources and mechanisms, electroactive platforms are categorized into i) direct electrical stimulation, ii) self‐powered electroactive systems, iii) physical stimuli‐mediated electroactive systems, and iv) conductive systems, and their applications in ...
Juwei Yang+4 more
wiley +1 more source
Physiotherapy and the South African heart transplant
Marylen R.I. Sternweiler
openalex +2 more sources
Immunodepressive serum treatment of acute heart transplant rejection. [PDF]
Alan S. Coulson+6 more
openalex +1 more source
Dipyridamole Acts as Clinical Ferroptosis Inhibitor to Prevent from Tissue Injury
Dipyridamole acts as a clinically used compound to suppress ferroptosis. Dipyridamole down‐regulates the expression of RNF126, which is an E3 ligase to ubiquitinate SLC7A11 for proteasome degradation. The deficiency of SLC7A11 largely abolishes the protective role of dipyridamole both in vitro and in vivo.
Xiao Zhuang+22 more
wiley +1 more source